Filtered By:
Condition: Allergy
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 129 results found since Jan 2013.
Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance
CONCLUSION: We demonstrate impaired immunity following SARS-CoV-2 mRNA immunization in a murine model of comorbid T2DM and obesity, supporting the need for further research into the basis for impaired anti-SARS-CoV-2 immunity in T2DM and investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseases.PMID:37595760 | DOI:10.1016/j.jaci.2023.06.031
Source: Clinical Lung Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Timothy R O'Meara Etsuro Nanishi Marisa E McGrath Soumik Barman Danica Dong Carly Dillen Manisha Menon Hyuk-Soo Seo Sirano Dhe-Paganon Robert K Ernst Ofer Levy Matthew B Frieman David J Dowling Source Type: research
Structural Framework for Analysis of CD4+ T-Cell Epitope Dominance in Viral Fusion Proteins
Biochemistry. 2023 Aug 9. doi: 10.1021/acs.biochem.3c00335. Online ahead of print.ABSTRACTAntigen conformation shapes CD4+ T-cell specificity through mechanisms of antigen processing, and the consequences for immunity may rival those from conformational effects on antibody specificity. CD4+ T cells initiate and control immunity to pathogens and cancer and are at least partly responsible for immunopathology associated with infection, autoimmunity, and allergy. The primary trigger for CD4+ T-cell maturation is the presentation of an epitope peptide in the MHC class II antigen-presenting protein (MHCII), most commonly on an a...
Source: Cancer Control - August 9, 2023 Category: Cancer & Oncology Authors: Samuel J Landry Ramgopal R Mettu Jay K Kolls Judith H Aberle Elizabeth Norton Kevin Zwezdaryk James Robinson Source Type: research
Updated Guidance Regarding The Risk ofAllergic Reactions to COVID-19 Vaccines and Recommended Evaluation and Management: A GRADE Assessment, and International Consensus Approach
J Allergy Clin Immunol. 2023 Jun 7:S0091-6749(23)00746-7. doi: 10.1016/j.jaci.2023.05.019. Online ahead of print.ABSTRACTThis guidance updates 2021 GRADE recomendations regarding immediate allergic reactions following COVID-19 vaccines and addresses re-vaccinating individuals with 1st dose allergic reactions and allergy testing to determine re-vaccination outcomes. Recent meta-analyses assessed the incidence of severe allergic reactions to initial COVID-19 vaccination, risk of mRNA-COVID-19 re-vaccination after an initial reaction, and diagnostic accuracy of COVID-19 vaccine and vaccine excipient testing in predicting reac...
Source: Clinical Lung Cancer - June 9, 2023 Category: Cancer & Oncology Authors: Matthew Greenhawt Timothy E Dribin Elissa M Abrams Marcus Shaker Derek K Chu David Bk Golden Cem Akin Akterini Anagnostou Faisal ALMuhizi Waleed Alqurashi Peter Arkwright James L Baldwin Aleena Banerji Philippe B égin Moshe Ben-Shoshan Jonathan Bernstein Source Type: research
Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine
Colloids Surf B Biointerfaces. 2022 Dec 20;222:113111. doi: 10.1016/j.colsurfb.2022.113111. Online ahead of print.ABSTRACTThroughout decades, the intrinsic power of the immune system to fight pathogens has inspired researchers to develop techniques that enable the prevention or treatment of infections via boosting the immune response against the target pathogens, which has led to the evolution of vaccines. The recruitment of Lipid nanoparticles (LNPs) as either vaccine delivery platforms or immunogenic modalities has witnessed a breakthrough recently, which has been crowned with the development of effective LNPs-based vacc...
Source: Colloids and Surfaces - December 31, 2022 Category: Biotechnology Authors: Ahmed A H Abdellatif Mahmoud A Younis Abdullah F Alsowinea Emad M Abdallah Mohamed S Abdel-Bakky Amal Al-Subaiyel Yasser A H Hassan Hesham M Tawfeek Source Type: research
In vitro and in vivo Evidence on Intra-tumor Injection of Allogeneic Serum for Immunotherapy in a Mouse Model of Colon Cancer
Iran J Allergy Asthma Immunol. 2022 Oct 26;21(5):549-560. doi: 10.18502/ijaai.v21i5.11042.ABSTRACTIt is believed that preformed antibodies are responsible for blood transfusion reactions and transplant rejections. In order to remove a tumor, the tissue must be rejected. On the basis of transfusion reaction and transplantation immunology, we hypothesized that allogeneic serum can inhibit tumor growth when injected intra-tumor. Initially, an in vitro cytotoxicity test was conducted using the C57BL/6 serum (intact or decomplemented) in combination with the BALB/c-originating CT26 cell line. The CT26 cell line was used to esta...
Source: Cancer Control - November 7, 2022 Category: Cancer & Oncology Authors: Erfan Basirat Danial Dehghan Ardeshir Abbasi Nafiseh Pakravan Source Type: research
